Skip to main content

Recently approved molecularly targeted therapies in AML

Publication ,  Journal Article
Papadantonakis, N; Erba, HP
Published in: ADVANCES IN CELL AND GENE THERAPY
April 2020

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

ADVANCES IN CELL AND GENE THERAPY

DOI

EISSN

2573-8461

ISSN

2573-8461

Publication Date

April 2020

Volume

3

Issue

2

Publisher

Hindawi Limited
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Papadantonakis, N., & Erba, H. P. (2020). Recently approved molecularly targeted therapies in AML. ADVANCES IN CELL AND GENE THERAPY, 3(2). https://doi.org/10.1002/acg2.76
Papadantonakis, Nikolaos, and Harry P. Erba. “Recently approved molecularly targeted therapies in AML.” ADVANCES IN CELL AND GENE THERAPY 3, no. 2 (April 2020). https://doi.org/10.1002/acg2.76.
Papadantonakis N, Erba HP. Recently approved molecularly targeted therapies in AML. ADVANCES IN CELL AND GENE THERAPY. 2020 Apr;3(2).
Papadantonakis, Nikolaos, and Harry P. Erba. “Recently approved molecularly targeted therapies in AML.” ADVANCES IN CELL AND GENE THERAPY, vol. 3, no. 2, Hindawi Limited, Apr. 2020. Crossref, doi:10.1002/acg2.76.
Papadantonakis N, Erba HP. Recently approved molecularly targeted therapies in AML. ADVANCES IN CELL AND GENE THERAPY. Hindawi Limited; 2020 Apr;3(2).

Published In

ADVANCES IN CELL AND GENE THERAPY

DOI

EISSN

2573-8461

ISSN

2573-8461

Publication Date

April 2020

Volume

3

Issue

2

Publisher

Hindawi Limited